|
1
|
Ahrens LC, Krabbenhøft MG, Hansen RW,
Mikic N, Pedersen CB, Poulsen FR and Korshoej AR: Effect of
5-aminolevulinic acid and sodium fluorescein on the extent of
resection in high-grade gliomas and brain metastasis. Cancers
(Basel). 14(617)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gandhi S, Meybodi AT, Belykh E, Cavallo C,
Zhao X, Syed MP, Moreira LB, Lawton MT, Nakaji P and Preul MC:
Survival outcomes among patients with high-grade glioma treated
with 5-aminolevulinic acid-guided surgery: A systematic review and
meta-analysis. Front Oncol. 9(620)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cordova JS, Gurbani SS, Holder CA, Olson
JJ, Schreibmann E, Shi R, Guo Y, Shu HK, Shim H and Hadjipanayis
CG: Semi-automated volumetric and morphological assessment of
glioblastoma resection with fluorescence-guided surgery. Mol
Imaging Biol. 18:454–462. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Richter JCO, Haj-Hosseini N, Hallbeck M
and Wårdell K: Combination of hand-held probe and microscopy for
fluorescence guided surgery in the brain tumor marginal zone.
Photodiagnosis Photodyn Ther. 18:185–192. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Patil CG, Walker DG, Miller DM, Butte P,
Morrison B, Kittle DS, Hansen SJ, Nufer KL, Byrnes-Blake KA, Yamada
M, et al: Phase 1 safety, pharmacokinetics, and fluorescence
imaging study of tozuleristide (BLZ-100) in adults with newly
diagnosed or recurrent gliomas. Neurosurgery. 85:E641–E649.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Valerio JE, de Jesús Aguirre Vera G,
Zumaeta J, Rea NS, Gomez MP, Mantilla-Farfan P, Valente L and
Alvarez-Pinzon AM: Comparative analysis of 5-ALA and fluorescent
techniques in high-grade glioma treatment. Biomedicines.
13(1161)2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Stummer W, Tonn JC, Mehdorn HM, Nestler U,
Franz K, Goetz C, Bink A and Pichlmeier U: ALA-Glioma Study Group.
Counterbalancing risks and gains from extended resections in
malignant glioma surgery: A supplemental analysis from the
randomized 5-aminolevulinic acid glioma resection study. Clinical
article. J Neurosurg. 114:613–623. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lau D, Hervey-Jumper SL, Chang S, Molinaro
AM, McDermott MW, Phillips JJ and Berger MS: A prospective phase II
clinical trial of 5-aminolevulinic acid to assess the correlation
of intraoperative fluorescence intensity and degree of histologic
cellularity during resection of high-grade gliomas. J Neurosurg.
124:1300–1309. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Stummer W, Nestler U, Stockhammer F, Krex
D, Kern BC, Mehdorn HM, Vince GH and Pichlmeier U: Favorable
outcome in the elderly cohort treated by concomitant temozolomide
radiochemotherapy in a multicentric phase II safety study of 5-ALA.
J Neurooncol. 103:361–370. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Picart T, Pallud J, Berthiller J, Dumot C,
Berhouma M, Ducray F, Armoiry X, Margier J, Guerre P, Varlet P, et
al: Use of 5-ALA fluorescence-guided surgery versus white-light
conventional microsurgery for the resection of newly diagnosed
glioblastomas (RESECT study): a French multicenter randomized phase
III study. J Neurosurg. 140:987–1000. 2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Acerbi F, Broggi M, Schebesch KM, Höhne J,
Cavallo C, De Laurentis C, Eoli M, Anghileri E, Servida M, Boffano
C, et al: Fluorescein-guided surgery for resection of high-grade
gliomas: A multicentric prospective phase II study (FLUOGLIO). Clin
Cancer Res. 24:52–61. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Schebesch KM, Höhne J, Rosengarth K, Noeva
E, Schmidt NO and Proescholdt M: Fluorescein-guided resection of
newly diagnosed high-grade glioma: Impact on extent of resection
and outcome. Brain Spine. 2(101690)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Francaviglia N, Iacopino DG, Costantino G,
Villa A, Impallaria P, Meli F and Maugeri R: Fluorescein for
resection of high-grade gliomas: A safety study control in a single
center and review of the literature. Surg Neurol Int.
8(145)2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Naik A, Smith EJ, Barreau A, Nyaeme M,
Cramer SW, Najafali D, Krist DT, Arnold PM and Hassaneen W:
Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for
resection of high-grade gliomas: A systematic review and network
meta-analysis. J Clin Neurosci. 98:240–247. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xi C, Jinli S, Jianyao M, Yan C, Huijuan
L, Zhongjie S, Zhangyu L, Liwei Z, Yukui L, Sifang C and Guowei T:
Fluorescein-guided surgery for high-grade glioma resection: A
five-year-long retrospective study at our institute. Front Oncol.
13(1191470)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Schupper AJ, Rao M, Mohammadi N, Baron R,
Lee JYK, Acerbi F and Hadjipanayis CG: Fluorescence-guided surgery:
A review on timing and use in brain tumor surgery. Front Neurol.
12(682151)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mansour HM, Shah S, Aguilar TM,
Abdul-Muqsith M, Gonzales-Portillo GS and Mehta AI: Enhancing
glioblastoma resection with NIR fluorescence imaging: A systematic
review. Cancers (Basel). 16(3984)2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Stummer W, Stepp H, Wiestler OD and
Pichlmeier U: Randomized, prospective double-blinded study
comparing 3 different doses of 5-aminolevulinic acid for
fluorescence-guided resections of malignant gliomas. Neurosurgery.
81:230–239. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Della Puppa A, Ciccarino P, Lombardi G,
Rolma G, Cecchin D and Rossetto M: 5-Aminolevulinic acid
fluorescence in high grade glioma surgery: Surgical outcome,
intraoperative findings, and fluorescence patterns. Biomed Res Int.
2014(232561)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cramer SW and Chen CC: Photodynamic
therapy for the treatment of glioblastoma. Front Surg.
6(81)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Molina ES and Brokinkel B: Letter to the
editor. Sodium fluorescein versus 5-aminolevulinic acid to
visualize high-grade gliomas. J Neurosurg. 133:1627–1630.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shi X, Zhang Z, Zhang Z, Cao C, Cheng Z,
Hu Z, Tian J and Ji N: Near-infrared window II fluorescence
image-guided surgery of high-grade gliomas prolongs the
progression-free survival of patients. IEEE Trans Biomed Eng.
69:1889–1900. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cesca BA, Martin KP, Caverzan MD, Oliveda
PM and Ibarra LE: State-of-the-art photodynamic therapy for
malignant gliomas: Innovations in photosensitizers and combined
therapeutic approaches. Explor Target Antitumor Ther.
6(1002303)2025.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tao T, Li G, Zhou K, Pan Q, Wu D, Lai L,
Gao M, Li S, Chen L, Han RPS, et al: Discovery of fatty acid
translocase CD36-targeting near-infrared fluorescent probe enables
visualization and imaging-guided surgery for glioma. Anal Chem.
97:3687–3695. 2025.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Panciani PP, Fontanella M, Schatlo B,
Garbossa D, Agnoletti A, Ducati A and Lanotte M: Fluorescence and
image guided resection in high grade glioma. Clin Neurol Neurosurg.
114:37–41. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Henderson F Jr, Belykh E, RaOS AD and
Schwartz TH: Qualitative head-to-head comparison of headlamp and
microscope for visualizing 5-ALA fluorescence during resection of
glioblastoma. Neurosurg Focus Video. 6(V7)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen L, Zhang J, Chi C, Che W, Dong G,
Wang J, Du Y, Wang R, Zhu Z, Tian J, et al: Lower-grade gliomas
surgery guided by GRPR-targeting PET/NIR dual-modality image probe:
A prospective and single-arm clinical trial. Theranostics.
14:819–829. 2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Inogés S, Tejada S, de Cerio AL,
Pérez-Larraya JG, Espinós J, Idoate MA, Domínguez PD, de Eulate RG,
Aristu J, Bendandi M, et al: A phase II trial of autologous
dendritic cell vaccination and radiochemotherapy following
fluorescence-guided surgery in newly diagnosed glioblastoma
patients. J Transl Med. 15(104)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chung IW and Eljamel S: Risk factors for
developing oral 5-aminolevulinic acid-induced side effects in
patients undergoing fluorescence guided resection. Photodiagnosis
Photodyn Ther. 10:362–367. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Feigl GC, Ritz R, Moraes M, Klein J,
Ramina K, Gharabaghi A, Krischek B, Danz S, Bornemann A, Liebsch M
and Tatagiba MS: Resection of malignant brain tumors in eloquent
cortical areas: a new multimodal approach combining
5-aminolevulinic acid and intraoperative monitoring. J Neurosurg.
113:352–357. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Roberts DW, Olson JD, Evans LT, Kolste KK,
Kanick SC, Fan X, Bravo JJ, Wilson BC, Leblond F, Marois M and
Paulsen KD: Red-light excitation of protoporphyrin IX fluorescence
for subsurface tumor detection. J Neurosurg. 128:1690–1697.
2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Valdés PA, Leblond F, Kim A, Harris BT,
Wilson BC, Fan X, Tosteson TD, Hartov A, Ji S, Erkmen K, et al:
Quantitative fluorescence in intracranial tumor: Implications for
ALA-induced PpIX as an intraoperative biomarker. J Neurosurg.
115:11–17. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nabavi A, Thurm H, Zountsas B, Pietsch T,
Lanfermann H, Pichlmeier U and Mehdorn M: 5-ALA Recurrent Glioma
Study Group. Five-aminolevulinic acid for fluorescence-guided
resection of recurrent malignant gliomas: A phase II study.
Neurosurgery. 65:1070–1076. 2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zimmermann A, Ritsch-Marte M and Kostron
H: mTHPC-mediated photodynamic diagnosis of malignant brain tumors.
Photochem Photobiol. 74:611–616. 2001.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li C, Sullivan PZ, Cho S, Nasrallah MP,
Buch L, Chen HC and Lee JYK: Intraoperative molecular imaging with
second window indocyanine green facilitates confirmation of
contrast-enhancing tissue during intracranial stereotactic needle
biopsy: A case series. World Neurosurg. 126:e1211–e1218.
2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hansen RW, Pedersen CB, Halle B, Korshoej
AR, Schulz MK, Kristensen BW and Poulsen FR: Comparison of
5-aminolevulinic acid and sodium fluorescein for intraoperative
tumor visualization in patients with high-grade gliomas: A
single-center retrospective study. J Neurosurg. 133:1324–1331.
2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zeppa P, De Marco R, Monticelli M, Massara
A, Bianconi A, Di Perna G, Crasto SG, Cofano F, Melcarne A, Lanotte
MM and Garbossa D: Fluorescence-guided surgery in glioblastoma:
5-ALA, SF or both? Differences between fluorescent dyes in 99
consecutive cases. Brain Sci. 12(555)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Eljamel MS, Goodman C and OSeley H: ALA
and Photofrin fluorescence-guided resection and repetitive PDT in
glioblastoma multiforme: A single centre Phase III randomised
controlled trial. Lasers Med Sci. 23:361–367. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mirza AB, Christodoulides I, Lavrador JP,
Giamouriadis A, Vastani A, Boardman T, Ahmed R, Norman I, Murphy C,
Devi S, et al: 5-Aminolevulinic acid-guided resection improves the
overall survival of patients with glioblastoma-a comparative cohort
study of 343 patients. Neurooncol Adv. 3(vdab047)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mirza AB, Lavrador JP, Christodoulides I,
Boardman TM, Vastani A, Al Banna Q, Ahmed R, Norman ICF, Murphy C,
Devi S, et al: 5-Aminolevulinic acid-guided resection in grade III
Tumors-A comparative cohort study. Oper Neurosurg (Hagerstown).
22:215–223. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sterne JAC, Savović J, Page MJ, Elbers RG,
Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge
SM, et al: RoB 2: A revised tool for assessing risk of bias in
randomised trials. BMJ. 366(l4898)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Martinez-Castellanos MA, Velez-Montoya R,
Price K, Henaine-Berra A, García-Aguirre G, Morales-Canton V and
Cernichiaro-Espinosa LA: Vascular changes on fluorescein
angiography of premature infants with low risk of retinopathy of
prematurity after high oxygen exposure. Int J Retina Vitreous.
3(2)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gautheron A, Bernstock JD, Picart T,
Guyotat J, Valdés PA and Montcel B: 5-ALA induced PpIX fluorescence
spectroscopy in neurosurgery: A review. Front Neurosci.
18(1310282)2024.PubMed/NCBI View Article : Google Scholar
|
![(A) Forest plot for postoperative
neurological deficit, with the results demonstrated a statistically
significant difference between groups [OR: 0.88, 95% CI:
(0.17,4.57), P<0.00001], but with heterogeneity (P=0.88,
I2=90%). (B) Funnel plots for Postoperative Neurological
deficit in the two groups with heterogeneity (P=0.88,
I2=90%). I2, percentage of total variation
across studies that is due to heterogeneity rather than chance; CI,
confidence interval; OR, odds ratio.](/article_images/mco/24/3/mco-24-03-02927-g01.jpg)
![(A) Forest plot for Postoperative KPS
≥70, with the results demonstrated a statistically significant
difference between groups [OR=49.46; 95% CI: (-2.21, 101.13);
P<0.00001] but with heterogeneity (P=0.06 and
I2=100%). (B) Funnel plots for Postoperative KPS≥70 in
the two groups with high heterogeneity (P=0.06 and
I2=100%). I2, percentage of total variation
across studies that is due to heterogeneity rather than chance; CI,
confidence interval; KPS, Karnofsky Performance Scale.](/article_images/mco/24/3/mco-24-03-02927-g02.jpg)
![(A) Forest plot for OS, with the
results demonstrated a statistically significant difference between
groups [OR=4.05; 95% CI: (1.33, 6.77); P<0.00001] but a high
heterogeneity was found (P<0.05 and I2=98%). (B)
Funnel plots for OS in the two groups with high heterogeneity
(P<0.05 and I2=98%). I2, percentage of
total variation across studies that is due to heterogeneity rather
than chance; CI, confidence interval; OS, overall survival.](/article_images/mco/24/3/mco-24-03-02927-g03.jpg)
